Metrics to compare | 217330 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship217330PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | −3.8x | −0.3x | |
PEG Ratio | −0.19 | −0.06 | 0.00 | |
Price/Book | 2.2x | 1.7x | 2.6x | |
Price / LTM Sales | 2.7x | 3.4x | 3.1x | |
Upside (Analyst Target) | - | 100.0% | 47.6% | |
Fair Value Upside | Unlock | 20.3% | 5.6% | Unlock |
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.